A New Approach to PCSK9 Therapeutics
Author:
Affiliation:
1. From the Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, New York, NY.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine,Physiology
Link
https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.117.310610
Reference15 articles.
1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
2. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease
3. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
4. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
5. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability;European Journal of Medicinal Chemistry;2024-02
2. New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist;Rational Pharmacotherapy in Cardiology;2023-12-28
3. Observational study of inclisiran effectiveness in Moscow healthcare;Russian Journal of Cardiology;2023-12-20
4. Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events;Frontiers in Cardiovascular Medicine;2023-06-26
5. Disorders of lipid metabolism. Clinical Guidelines 2023;Russian Journal of Cardiology;2023-06-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3